Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery

Abstract

Psoriasis is linked with unusual differentiation and hyperproliferation of epidermal keratinocytes that significantly impair the quality of life (QoL) of patients. The present treatment options only provide symptomatic relief and are surrounded by various adverse effects. Recently, nanostructured lipid carriers (NLCs) have emerged as next-generation nanocarriers with better physicochemical characteristics. The current manuscript provides background information on psoriasis, its pathophysiology, existing treatment options, and its limitations. It highlights the advantages, rationale, and mechanism of the permeation of NLCs for the treatment of psoriasis. It further gives a detailed account of various NLC nanoformulations for the treatment of psoriasis. In addition, tabular information is provided on the most relevant patents on NLCs for treating psoriasis. Lastly, light is shed on regulatory considerations related to NLC-like nanoformulations. In the treatment of psoriasis, NLCs display a sustained release drug profile, an ability to incorporate both hydrophobic and hydrophilic drugs, an enhancement in skin hydration, penetrability, retention, and bioavailability of the drug, along with reduced staining potential as compared to conventional ointments, and decreased side effects of drug molecules. This affirms the bright future of NLC nanoformulations in the treatment of psoriasis. However, academic industry collaboration and more sound regulatory controls are required to commercialize the NLC nanoformulations for psoriasis treatment.

Pathology and Treatment of Psoriasis Using Nanoformulations

“…As a result, various studies are concentrating on designing PSO-specific microbiome-based therapeutics. Artificial intelligence and neural networks: There is growing curiosity about employing artificial intelligence and machine learning to create improved psoriatic evaluations and therapy methodologies [ 103 ]. …”

“…Artificial intelligence and neural networks: There is growing curiosity about employing artificial intelligence and machine learning to create improved psoriatic evaluations and therapy methodologies [ 103 ].…”

Co-delivery of Tacrolimus and Thymoquinone topically by Nanostructured lipid carriers gel for enhanced efficacy against imiquimod-induced psoriasis in Balb/c mice

“…These carriers exhibit signi cant potential for addressing various skin conditions by interacting with the skin at the molecular level [21]. Among different lipid-based nanoparticles, nanostructured lipid carriers (NLCs) are recognized as highly e cient options for delivering topical anti-psoriatic drugs [22]. NLCs offer additional advantages, including enhanced drug loading, improved release pro les, and greater stability of the encapsulated compounds compared to other lipid nanoparticles [23,24].…”

Causal relationship between psoriasis vulgaris and dementia: Insights from Mendelian randomization analysis

“…Psoriasis is a chronic skin disease characterized by more than skin hyperplasia with obvious changes in the skin, such as rashes, scales, red plaques and itching 1,2 . Among the four subtypes of psoriasis, the most common is psoriasis vulgaris, which accounts for 80%–90% of all cases 3,4 . Dementia presents a significant challenge to patients, their caregivers and healthcare systems at large 5 .…”

“…1,2 Among the four subtypes of psoriasis, the most common is psoriasis vulgaris, which accounts for 80%-90% of all cases. 3,4 Dementia presents a significant challenge to patients, their caregivers and healthcare systems at large. 5 The estimated global prevalence of dementia is approximately 50 million in 2020, with a projected increase to 152 million by the year 2050.…”